384 results about "RNA virus" patented technology

The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.

The invention provides a primer, a probe and a kit for detecting a novel coronavirus. The specific primer and the probe are designed according to an ORF1ab gene, an E gene, an N gene, an S gene and anM gene of the novel coronavirus 2019-nCoV and are used for identifying and detecting the novel coronavirus. The specific primer/probe and the kit for detecting the 2019-nCoV are high in sensitivity,precision and accuracy, good in specificity and stability, small in template amount required by detection and objective and accurate in detection result. The five-target design can well overcome falsenegative caused by variation in the RNA virus passage process, the positive detection rate can be effectively improved, and missing detection is avoided as much as possible. High clinical applicationvalues are realized.

The present invention relates to a method of preventing or inhibiting viral infection of a cell and/or fusion between the envelope of a virus and the membranes of a cell targeted by the virus (thereby preventing delivery of the viral genome into the cell cytoplasm, a step required for. viral infection). The present invention particularly relates to the families of RNA viruses, including the arenaviruses, coronaviruses, filoviruses, orthomyxoviruses, paramyxoviruses, and retroviruses, having Class I membrane fusion proteins as the fusion proteins that mediate this fusion process. The present invention provides for a method of identifying a conserved motif or domain called the fusion initiation region (FIR) in these viruses. The present invention further provides for methods of preventing infection by such viruses, by interfering with their FIR. The present invention further provides for methods of treatment and prophylaxis of diseases induced by such viruses.

The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.

An infectious clone based on the genome of a wild-type RNA virus is produced by the process of providing a host cell not susceptible to infection by the wild-type RNA virus, providing a recombinant nucleic acid based on the genome of the wild-type RNA virus, transfecting the host cell with the recombinant nucleic acid and selecting for infectious clones. The recombinant nucleic acid comprises at least one full-length DNA copy or in vitro-transcribed RNA copy or a derivative of either. The infectious clones can be used in single or dual purpose vaccines and in viral vector vaccines.

The present invention discloses an RNA virus inactivation preservation solution. The inactivation preservation solution comprises ammonium salt, 1-ethyl-3-methylimidazolium bisulfate, lithium chloride, ethylenediaminetetraacetic acid, an RNase inhibitor, a surfactant, a reducing agent, a buffer agent and water. The present invention also provides an RNA virus sample inactivation and preservation method and an RNA virus detection method, and the method is conducted by using the inactivation preservation solution. The preservation solution has low cost, inhibits RNase activity, preserves RNA integrity, realizes preservation and transportation of samples at room temperature, can also quickly inactivate pathogens at room temperature, reduces infection risks of medical personnel, and reduces false negatives in detection. At the same time, the inactivation preservation solution can realize a lysis function, does not contain chaotropic reagents and alcohols, is compatible with mainstream nucleic acid extraction kits on the market, greatly saves time of an entire process, and is particularly suitable for 2019 new coronavirus (COVID-19) inactivation and lysis steps after swab sampling.

The invention generally relates to recombinant polynucleotides, positive-strand RNA virus (psRNAV) recombinant expression vectors, and packaging systems. The packaging systems are based on the expression of helper functions by coinfecting re-combinant poxvirus vectors comprising recombinant polynucleotides. Methods for obtaining psRNAV replicon particles using these packaging systems are disclosed. Immunogenic compositions and pharmaceutical formulations are provided that comprise replicon particles of the invention. Methods for generating an immune response or producing a pharmaceutical effect are also provided.

The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.

The invention relates to a multiplex PCR (polymerase chain reaction) primer, a probe and a gene chip for detecting the bluetongue virus, foot and mouth disease virus and bovine viral diarrhea virus. The multiplex PCR primer and probe have the nucleotide sequences shown by SEQ ID No.1 to SEQ ID and No.9. The gene chip comprises a solid-phase carrier, a sample application quality control probe, a positive hybrid quality control probe and a multiplex PCR primer for detecting the bluetongue virus, foot and mouth disease virus and bovine viral diarrhea virus and the corresponding probe. In the invention, the forward primers of three viruses are marked with fluorescence, a gene chip detection technology carrying three viruses in animal fur is established based on multiplex RT-PCR (reverse transcription-polymerase chain reaction), and the RNA virus in the fur can be sensitively and specifically detected with high flux; the three viruses are screened at the same time in detection once, and the situation that a specific method is required for each virus before is changed, thereby saving the diagnosis time, meeting the needs for quick detection of mass imported/exported fur samples of the exit-entry inspection and quarantine departments and the fur import and export enterprises, and realizing relatively high application values.

The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs in the prevention and treatment of a disease caused by a pathogen, for example, a DNA or RNA virus.

The invention discloses L-nucleoside compounds having the structure characteristic represented by the formula (I) or pharmaceutically acceptable salts thereof, and belongs to the technical field of pharmaceutical chemistry. The compounds can inhibit the activity of RNA viral polymerase, so the compounds can be used as potential drugs for prevention and treatment of infection of RNA viruses such as HCV, influenza virus, HRV (rhinovirus), RSV, Ebola virus, dengue virus, intestinal virus and the like.

A vaccine for West Nile virus that protects a subject against West Nile infection comprising an a pharmaceutically acceptable carrier and a therapeutically effective does of an infectious agent selected from the group consisting of: a live attenuated infectious (+) RNA virus designated as WN1415, a vector comprising infectious DNA encoding an infectious (+) RNA molecule encoding the West Nile virus, and the West Nile (+) RNA virus designated as WN956D117B3 (GenBank #M12294).

The invention provides a method for co-extracting DNA/RNA (Deoxyribonucleic Acid/Ribonucleic Acid) virus nucleic acid. The method comprises the following steps: cracking a sample, which is diluted with saline, with a guanidine isothiocyanate cracking solution containing an RNA precipitating aid agent; releasing and dissociating DNA or RNA of different nucleic acid viruses in the sample into a cracking solution; adding magnetic beads to form a magnetic bead-nucleic acid compound; washing to obtain a nucleic acid eluting solution. The novel method for co-extruding the DNA and the RNA from a respiratory tract sample is established based on the nano magnetic beads; in a whole process, toxic reagents including phenol, chloroform, beta-mercaptoethanol and the like are not used, and time and labor are saved. The method is used for commonly extracting the DNA and the RNA from the respiratory tract sample and is also applicable to nucleic acid co-extraction of other samples with different types, such as urine and blood; impurities including protein and the like are efficiently removed and the degradation of the nucleic acid is reduced; the aim of detecting DNA viruses and RNA viruses in the same tube at the same time is realized. The method is simple, convenient, rapid and safe, and is particularly suitable for fluorescent quantitative PCR (Polymerase Chain Reaction) detection and the like.

The invention discloses a method of simultaneously extracting animal DNA (Deoxyribonucleic Acid) virus and RNA (Ribonucleic Acid) virus nucleic acid in blood serum and double swabs. The method comprises the following steps of: carrying out lysis on a to-be-extracted substance by using guanidinium isothiocyanate lysate; adsorbing RNA by a silica gel membrane; removing impure protein by washing liquor I; removing impurities by washing liquor II; carrying out DEPC (Diethylpyrocarbonate) water-washing to remove nucleic acid, wherein the guanidinium isothiocyanate lysate comprises 3M-7M guanidinium isothiocyanate, 0.6%-1.0% TriTon-100, 30mM-50mM Tris-Cl, 5mM-15mM DTT (DL-Dithiothreitol), 60 mu g/mL-90 mu g/mL protease K, 10mM-30mM EDTA (Ethylene Diamine Tetraacetic Acid), and PH of the guanidinium isothiocyanate lysate is 4.3-4.6; the washing liquor I comprises 5M-6M guanidine hydrochloride, 53%-59% absolute ethyl alcohol, 70-90 mu g/mL protease K, and PH of the washing liquor I is 6.4-6.6; the washing liquor II comprises 70%-80% alcohol. The method disclosed by the invention has the advantages of being simple in extracting process, short in period, low in cost, and capable of simultaneously extracting RNA virus and DNA virus nucleic acid in an animal blood serum sample and a double-swab sample.

The invention discloses a coliphage MS2 standard sample. The concentration of the coliphage MS2 standard sample is 1.57*1011 pfu/mL, and the standard sample can be used as a quality control substance for the detection process when food-borne RNA viruses are detected. According to a preparing method of the coliphage MS2 standard sample, evenness and stability are tested, and the guarantee period is 12 months.

The invention discloses a recombinant plant rhabdovirus vector and a construction method thereof. The recombinant plant rhabdovirus vector comprises a modified plant rhabdovirus genome, a transcription unit which is induced newly and a heteroduplex nucleotide sequence, wherein the transcription unit is inserted into the plant rhabdovirus genome to express the heteroduplex nucleotide sequence, the heteroduplex nucleotide sequence is replaced into a glycoprotein transcription unit of a recombinant plant rhabdovirus; the recombinant plant rhabdovirus has copying and infecting capacity, and one antigenic polypeptide or other protein is coded by the heteroduplex nucleotide sequence. The virus expression vector is the first one which can express a negative-sense RNA virus vector of foreign protein on plants, and the recombinant plant rhabdovirus vector has the advantages that the expression quantity is high, the expression stability is good, a relative long foreign gene segment can be inserted, and inserted foreign gene segment is not prone to loosing; the recombinant plant rhabdovirus vector can be used for expressing of multiple kinds of foreign protein and can also be used for preparing animal vaccines, and wide application values and application prospects are achieved.

A process for replicating or for replicating and expressing a sequence of interest in a plant, comprising: (i) an RNA replicon or a precursor thereof, said RNA replicon being derived from a plus-sense single stranded RNA virus and comprising at least one sequence of interest; and (ii) a helper replicon, or a precursor thereof, wherein said helper replicon is (a) incapable of systemic movement in said plant both in the presence and in the absence of said RNA replicon (i) and (b) capable of expressing in a plant one or more proteins necessary for systemic movement of said RNA replicon (i), whereby said RNA replicon (i) is capable of replicating or replicating and expressing said sequence of interest in said plant, but unable to move systemically in said plant in the absence of said one or more proteins expressed by said helper replicon (ii).

The invention provides application of dicycloplatin in preparation of an antiviral drug and/or antibacterial drug and application of the dicycloplatin in preparation of an antiviral adjuvant drug and/or antibacterial adjuvant drug. Viruses related in the invention are RNA viruses such as hepatitis B virus, hepatitis C virus, human immunodeficiency virus and influenza virus, and the antibacterial drug is resistant to mycobacterium tuberculosis and/or nontuberculosis mycobacteria, Research results prove that dicycloplatin has the effect of resisting multiple bacteria and viruses, especially has obvious inhibitory effect on drug-resistance bacteria, no obvious cytotoxicity and high medication safety.

The invention provides a screening method of a sgRNA (small guide ribonucleic acid) efficient action target based on a CRISPR-Cas13d (clustered red regularly interspaced short palindromic repeat) system and application, and particularly application in RNA virus knockdown. According to the screening method, two expression read frame sequences ORF4 and ORF5 of a PRRSV are respectively fused with a carbon end of a mCherry gene through a mCherry fluorescence report gene, a fluorescence report system for screening sgRNA efficient action targets of the CRISPR-Cas13d system is established, and by virtue of the property that mRNA is efficiently cut by CRISPR-Cas13d, rapid screening of sgRNAs with high efficiency is implemented. Additionally, PRRSV-GFP recombinant viruses are efficiently degraded by using the screened efficient targetedly combined sgRNA based on the CRISPR-Cas13d system. The RNA virus knockdown method provided by the invention has the advantages of being high in efficiency, high in precision and low in target missing rate.